Contract Pharma: Altasciences Appoints Dr. Bruce Frank as VP, CDMO Operations

Alzamend Neuro Announces It Has Contracted with Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer's Disease in September 2021

Proactive: Emyria Signs Pure CBD Agreement with U.S.-based Altasciences to Help Fast Track Registration

Proactive: Emyria to Accelerate FDA and TGA CBD Registration Programs with Altasciences Deal

.custom-column-left-text { float: left; width: 50%; padding-right: 10px; } .custom-column-right-text { float: right; width: 45%; text-align:center; } @media only screen and (max-width: 600px) { .custom-column-left-text, .custom-column-right-text, .custom-column-flc-ebook-text { float:none; width:80%; margin:0 auto; } }

Dr.

.custom-column-left-text { float: left; width: 50%; padding-right: 10px; } .custom-column-right-text { float: right; width: 45%; text-align:center; } @media only screen and (max-width: 600px) { .custom-column-left-text, .custom-column-right-text, .custom-column-flc-ebook-text { float:none; width:80%; margin:0 auto; } }

In our February 2021 blog we discussed protocol design concepts for ethnobridging in Phase I clinical trials.

Subscribe to